Human IL-4 R alpha / CD124 Protein, His Tag (MALS verified)
分子別名(Synonym)
IL4R,CD124,IL4RA
表達(dá)區(qū)間及表達(dá)系統(tǒng)(Source)
Human IL-4 R alpha, His Tag (ILR-H5221) is expressed from human 293 cells (HEK293). It contains AA Met 26 - His 232 (Accession # NP_000409.1).
Predicted N-terminus: Met 26
蛋白結(jié)構(gòu)(Molecular Characterization)
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 24.6 kDa. The protein migrates as 36-50 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.
內(nèi)毒素(Endotoxin)
Less than 1.0 EU per μg by the LAL method.
純度(Purity)
>95% as determined by SDS-PAGE.
制劑(Formulation)
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
重構(gòu)方法(Reconstitution)
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存儲(Storage)
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.
背景(Background)
IL-4是一種多效性細(xì)胞因子,由活化的Th2細(xì)胞和肥大細(xì)胞產(chǎn)生,在免疫反應(yīng)中發(fā)揮關(guān)鍵作用。IL-4的作用是在與存在于造血細(xì)胞和非造血細(xì)胞上的高親和力受體復(fù)合物結(jié)合后介導(dǎo)的。造血細(xì)胞對IL-4的反應(yīng)是由一種高親和力受體復(fù)合物介導(dǎo)的,該復(fù)合物由140 kDa的IL4Rα(CD124)亞基和70 kDa常見細(xì)胞因子γc鏈(CD132)組成。
白細(xì)胞介素4受體(IL4R)也稱為CD124、IL4Rα和BSF受體,是一種由活化的Th2細(xì)胞和肥大細(xì)胞產(chǎn)生的I型細(xì)胞因子受體,在Th2偏向性免疫反應(yīng)、替代巨噬細(xì)胞活化、粘膜免疫、過敏性炎癥、腫瘤進(jìn)展和動脈粥樣硬化形成中發(fā)揮重要作用。編碼的IL4R蛋白的可溶性形式可以通過交替剪接變體或通過膜結(jié)合蛋白的蛋白水解產(chǎn)生,并且這種可溶性形式可以抑制IL4介導(dǎo)的細(xì)胞增殖和T細(xì)胞上調(diào)IL5。IL4R可以選擇性地與IL13Ra1結(jié)合以形成對IL4和IL13都有反應(yīng)的II型受體。白細(xì)胞介素-4受體已被證明與SHC1相互作用。
關(guān)鍵字: IL-4Ra;IL-4Ra蛋白;IL-4Ra重組蛋白;ACRO;百普賽斯;
百普賽斯集團(tuán)ACROBiosystems Group(股票代碼:301080)是成立于2010年的跨國生物科技公司,是為全球生物醫(yī)藥、健康產(chǎn)業(yè)領(lǐng)域提供關(guān)鍵生物試劑產(chǎn)品及解決方案的行業(yè)平臺型基石企業(yè)。2021年在創(chuàng)業(yè)板上市。百普賽斯集團(tuán)業(yè)務(wù)遍布全球,橫跨亞洲、北美洲、歐洲,在中國、美國、瑞士等12個城市設(shè)有辦公室、研發(fā)中心及生產(chǎn)基地。目前累計(jì)服務(wù)客戶超6000家,與全球Top 20醫(yī)藥企業(yè)均建立了長期、穩(wěn)定的合作伙伴關(guān)系。集團(tuán)旗下?lián)碛衅放艫CROBiosystems百普賽斯、bioSeedin柏思薈、Condense Capital墾拓資本和ACRODiagnostics百斯醫(yī)學(xué)等。